CD8A and diffuse large B-cell lymphoma: The results obtained showed that CD8+ NKs, but not CD8- NKs, are associated with complete responses and, more importantly, with overall survival (OS), representing a promising new biomarker with prediction and prognosis potential in R/R DLBCL.